Sab Biotherapeutics, INC Schedule 13G passive stakes

Caligan Partners LP and David Johnson have reported beneficial ownership of 7,967,207 shares, representing 8.8% of SAB Biotherapeutics, Inc. common stock.

Vivo Opportunity Fund Holdings, L.P. and its affiliates have disclosed beneficial ownership of 9.99% of SAB Biotherapeutics, Inc. common stock, including convertible securities and warrants.

Woodline Partners LP has filed a Schedule 13G, revealing beneficial ownership of 6.8% of SAB Biotherapeutics, Inc. common stock, including shares issuable from warrants and preferred stock.

Balyasny Asset Management L.P. and affiliated entities have reported an adjustment in their beneficial ownership of SAB Biotherapeutics, Inc. common stock, now holding 9.45%.

Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, has reported beneficial ownership of 6,405,553 shares, representing 8.38% of SAB Biotherapeutics, Inc.'s common stock as of June 30, 2026.

Caligan Partners LP and David Johnson have reported beneficial ownership of 10.4% of SAB Biotherapeutics, Inc. common stock as of March 31, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5,089,939 shares of SAB Biotherapeutics, Inc. common stock, representing 9.99% of the class.

Millennium Management LLC and Israel A. Englander have reported a 5.1% beneficial ownership stake in SAB Biotherapeutics, Inc.

RTW Investments and Roderick Wong report a 3.2% beneficial ownership stake in SAB Biotherapeutics, Inc., including convertible warrants.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. reported a 7.3% beneficial ownership stake in SAB Biotherapeutics, Inc. common stock.

A group of investment funds and entities managed by BVF Partners L.P. reported a combined beneficial ownership of 9.99% in SAB Biotherapeutics, Inc. common stock.

Woodline Partners LP has reported a 9.9% beneficial ownership stake in SAB Biotherapeutics, Inc., primarily through common stock and convertible warrants.

Commodore Capital LP and its affiliates have reported a 9.9% beneficial ownership stake in SAB Biotherapeutics, Inc., primarily through converted Series B Preferred Stock.

Vivo Opportunity Funds disclose a combined 9.99% beneficial ownership in SAB Biotherapeutics, primarily through convertible preferred stock and warrants.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have reported a 9.99% beneficial ownership stake in SAB Biotherapeutics, Inc., holding 1,024,335 shares of common stock.